PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Brenner, E.* ; Schörg, B.F.* ; Ahmetlic, F. ; Wieder, T.* ; Hilke, F.J.* ; Simon, N.* ; Schroeder, C.* ; Demidov, G.* ; Riedel, T.* ; Fehrenbacher, B.* ; Schaller, M.* ; Forschner, A.* ; Eigentler, T.* ; Niessner, H.* ; Sinnberg, T.* ; Böhm, K.S.* ; Hömberg, N. ; Braumüller, H.* ; Dauch, D.* ; Zwirner, S.* ; Zender, L.* ; Sonanini, D.* ; Geishauser, A. ; Bauer, J.* ; Eichner, M.* ; Jarick, K.J.* ; Beilhack, A.* ; Biskup, S.* ; Döcker, D.* ; Schadendorf, D.* ; Quintanilla-Martinez, L.* ; Pichler, B.J.* ; Kneilling, M.* ; Mocikat, R. ; Röcken, M.*

Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours.

Nat. Commun. 11:1335 (2020)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Immune checkpoint blockade (ICB)-based or natural cancer immune responses largely eliminate tumours. Yet, they require additional mechanisms to arrest those cancer cells that are not rejected. Cytokine-induced senescence (CIS) can stably arrest cancer cells, suggesting that interferon-dependent induction of senescence-inducing cell cycle regulators is needed to control those cancer cells that escape from killing. Here we report in two different cancers sensitive to T cell-mediated rejection, that deletion of the senescence-inducing cell cycle regulators p16(Ink4a)/p19(Arf) (Cdkn2a) or p21(Cip1) (Cdkn1a) in the tumour cells abrogates both the natural and the ICB-induced cancer immune control. Also in humans, melanoma metastases that progressed rapidly during ICB have losses of senescence-inducing genes and amplifications of senescence inhibitors. Metastatic cells also resist CIS. Such genetic and functional alterations are infrequent in metastatic melanomas regressing during ICB. Thus, activation of tumour-intrinsic, senescence-inducing cell cycle regulators is required to stably arrest cancer cells that escape from eradication.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
12.121
2.847
25
46
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Cd4(+) T-cells; Pd-1 Blockade; Checkpoint Blockade; Immunotherapy; Melanoma; Resistance; Rna; Surveillance; Mechanisms; Responses
Sprache englisch
Veröffentlichungsjahr 2020
HGF-Berichtsjahr 2020
ISSN (print) / ISBN 2041-1723
e-ISSN 2041-1723
Zeitschrift Nature Communications
Quellenangaben Band: 11, Heft: 1, Seiten: , Artikelnummer: 1335 Supplement: ,
Verlag Nature Publishing Group
Verlagsort London
Begutachtungsstatus Peer reviewed
Institut(e) AG Translationale Molekulare Immunologie (TMI)
Institute of Molecular Immunology (IMI)
POF Topic(s) 30203 - Molecular Targets and Therapies
30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-501711-001
G-501700-006
DOI 10.1038/s41467-020-14987-6
WOS ID WOS:000563526500001
Scopus ID 85081715323
PubMed ID 32165639
Erfassungsdatum 2020-04-23
[➜Korrektur melden]